Personalized Prophylactic Antiemetic Regimens for Control of Chemotherapy-Induced Nausea and Vomiting by Pharmacogenetic Analysis of Three Receptor Genes: <i>HTR3A</i> , <i>HTR3B</i> , <i>TACR1</i>
The present study confirmed our hypothesis that among Chinese patients with breast cancer who received AC, the selection of optimal antiemetic prophylaxis may be aided by assessing an individual's pharmacogenetic profile. It also highlights a novel digenic interaction that has not been known before for pharmacogenetic analysis.
Authors
- Frankie Mo (ORCID: https://orcid.org/0000-0002-0566-3212)
- Winnie Yeo (ORCID: https://orcid.org/0000-0002-0863-8469)
- W.H. Ko (ORCID: https://orcid.org/0000-0002-2041-402X)
- L. Li
- Jinghan Huang (ORCID: https://orcid.org/0000-0003-0628-6022)
- Suk Ling (ORCID: https://orcid.org/0000-0001-6175-5691)
- Nelson L.S. Tang (ORCID: https://orcid.org/0000-0002-3607-5819)
- Kwai T. Lai
- Horatio L. Yeo
- Elizabeth Pang
- Manman Ou
- Thomas K.H. Lau
Institutions
- Chinese University of Hong Kong (HK)
- Prince of Wales Hospital (CN)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1200/po-24-00858
- Citations
- 1
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 2.01